Alluvi, previously BI 4744, represents a promising development in obesity care. This dual activator targeting both GLP-1 and GIP sites demonstrates remarkable efficacy in research assessments, possibly outperforming https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/